Skip to main content
Top
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

Epidemiology of invasive pneumococcal disease in indigenous and non-indigenous adults in northwestern Ontario, Canada, 2006–2015

Authors: Daniel Dalcin, Lee Sieswerda, Sacha Dubois, Marina Ulanova

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

Despite the use of pneumococcal vaccines, indigenous populations are consistently disproportionately affected by invasive pneumococcal disease (IPD). With recent changes in Ontario’s provincial pneumococcal vaccination program, we sought to evaluate the epidemiology and burden of IPD in northwestern Ontario (NWO) Canada – a region that contains a substantial (19.2%) indigenous population.

Methods

We retrospectively reviewed all adult cases of IPD that were reported to the Thunder Bay District Health Unit, in Thunder Bay, Ontario, Canada, over a 10-year period (2006–2015). Patients admitted to the Thunder Bay Regional Health Sciences Centre with IPD had their charts reviewed to abstract clinical data. Statistical analysis, including incidence rates of IPD, was performed.

Results

Two hundred sixty-two cases of IPD occurred over the 10-year observation period and clinical data was available for 182 cases. Fifty-three of 182 (29.1%) patients were indigenous. 73 of 182 (40.1%) of patients were immunocompromised. Indigenous patients with IPD were more likely to be immunocompromised than non-indigenous patients (p < 0.001). Serotype data was available for 159 cases of IPD; PCV7, PCV13, and PPV23 covered 5.7%, 28.3%, and 79.2% of isolates, respectively, while 29 (20.8%) were non-vaccine serotypes. The annual incidence rate of IPD ranged from 8.9 to 25.9 per 100,000 among adults 18–64 years old; among adults 65 years of age and older the annual incidence of IPD ranged from 18.5 to 60.7 per 100,000.

Conclusion

Among adults in NWO, Canada, there is a high incidence of IPD. Immunocompromised indigenous adults in NWO may benefit from pneumococcal vaccination coverage. Emerging non-vaccine serotypes of Streptococcus pneumoniae warrant the consideration of the provincial pneumococcal vaccination program.
Literature
1.
go back to reference Drikoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(S5):45–51.CrossRef Drikoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(S5):45–51.CrossRef
2.
go back to reference GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Infect Dis. 2018;S1473-3099(18)30310-4. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Infect Dis. 2018;S1473-3099(18)30310-4.
4.
go back to reference Bruce MG, Deeks SL, Zulz T, Bruden D, Navarro C, Lovgren M, et al. International circumpolar surveillance system for invasive pneumococcal disease, 1999-2005. Emerg Infect Dis. 2008;14:25–33.CrossRefPubMedPubMedCentral Bruce MG, Deeks SL, Zulz T, Bruden D, Navarro C, Lovgren M, et al. International circumpolar surveillance system for invasive pneumococcal disease, 1999-2005. Emerg Infect Dis. 2008;14:25–33.CrossRefPubMedPubMedCentral
5.
go back to reference Lehmann D, Willis J, Moore HC, Giele C, Murphy G, Keil AD, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal Western Australians from 1997 through 2007 and emergence of non-vaccine serotypes. Clin Infect Dis. 2010;50:1477–86.CrossRefPubMed Lehmann D, Willis J, Moore HC, Giele C, Murphy G, Keil AD, et al. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal Western Australians from 1997 through 2007 and emergence of non-vaccine serotypes. Clin Infect Dis. 2010;50:1477–86.CrossRefPubMed
6.
go back to reference Segal N, Greenberg D, Dagan R, Ben-Shimol S. Disparities in PCV impact between different ethnic populations cohabiting in the same region: a systematic review of the literature. Vaccine. 2016;34:4371–7.CrossRefPubMed Segal N, Greenberg D, Dagan R, Ben-Shimol S. Disparities in PCV impact between different ethnic populations cohabiting in the same region: a systematic review of the literature. Vaccine. 2016;34:4371–7.CrossRefPubMed
7.
go back to reference Ya L, Martin I, Tsang R, Squires SG, Demczuk W, Desai S. Invasive bacterial diseases in northern Canada, 2006-2013. Can Comm Dis Rep. 2016;42:74–80.CrossRef Ya L, Martin I, Tsang R, Squires SG, Demczuk W, Desai S. Invasive bacterial diseases in northern Canada, 2006-2013. Can Comm Dis Rep. 2016;42:74–80.CrossRef
8.
go back to reference Singleton RJ, Hennessey TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by non-vaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784–92.CrossRefPubMed Singleton RJ, Hennessey TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by non-vaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784–92.CrossRefPubMed
9.
go back to reference Weatherholtz R, Millar EV, Moulton LH, et al. Invasive pneumococcal disease a decade after a pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis. 2010;50:1238–46.CrossRefPubMed Weatherholtz R, Millar EV, Moulton LH, et al. Invasive pneumococcal disease a decade after a pneumococcal conjugate vaccine use in an American Indian population at high risk for disease. Clin Infect Dis. 2010;50:1238–46.CrossRefPubMed
14.
go back to reference Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016;62:139–47.CrossRefPubMed Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016;62:139–47.CrossRefPubMed
15.
go back to reference Slotved HC, Kaltoft M, Skovsted IC, Kern MB, Espersen F. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-latex). J Clin Microbiol. 2004;42(6):2518–22.CrossRefPubMedPubMedCentral Slotved HC, Kaltoft M, Skovsted IC, Kern MB, Espersen F. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-latex). J Clin Microbiol. 2004;42(6):2518–22.CrossRefPubMedPubMedCentral
16.
go back to reference Invasive pneumococcal disease, Notifiable Diseases Online. Public Health Agency of Canada. 2017 [cited December 15, 2017]. Available from https://www.canada.ca/en/public-health/services/immunization/vaccine-preventable-diseases/invasive-pneumococcal-disease/health-professionals.html Invasive pneumococcal disease, Notifiable Diseases Online. Public Health Agency of Canada. 2017 [cited December 15, 2017]. Available from https://​www.​canada.​ca/​en/​public-health/​services/​immunization/​vaccine-preventable-diseases/​invasive-pneumococcal-disease/​health-professionals.​html
17.
go back to reference Desai S, Policarpio ME, Wong K, Gubbay J, Fediurek J, Deeks S. The epidemiology of invasive pneumococcal disease in older adults from 2007 to 2014 in Ontario, Canada: a population based study. CMAJ Open. 2016;4:E545–50.CrossRefPubMedPubMedCentral Desai S, Policarpio ME, Wong K, Gubbay J, Fediurek J, Deeks S. The epidemiology of invasive pneumococcal disease in older adults from 2007 to 2014 in Ontario, Canada: a population based study. CMAJ Open. 2016;4:E545–50.CrossRefPubMedPubMedCentral
18.
go back to reference Moberley S, Krause V, Cook H, Mulholland K, Carapetis J, Torzillo P, et al. Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in indigenous adults in the Northern Territory of Australia. Vaccine. 2010;28:2296–301.CrossRefPubMed Moberley S, Krause V, Cook H, Mulholland K, Carapetis J, Torzillo P, et al. Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in indigenous adults in the Northern Territory of Australia. Vaccine. 2010;28:2296–301.CrossRefPubMed
19.
go back to reference Duvvuri VR, Deng X, Teatero S, Memari N, Athey T, Fittipaldi N, et al. Population structure and drug resistance patterns of emerging non-PCV-13 Streptococcus pneumoniae serotypes 22F, 15A, and 8 isolated from adults in Ontario, Canada. Infect Genet Evol. 2016;42:1–8.CrossRefPubMed Duvvuri VR, Deng X, Teatero S, Memari N, Athey T, Fittipaldi N, et al. Population structure and drug resistance patterns of emerging non-PCV-13 Streptococcus pneumoniae serotypes 22F, 15A, and 8 isolated from adults in Ontario, Canada. Infect Genet Evol. 2016;42:1–8.CrossRefPubMed
20.
go back to reference Golden AR, Adam HJ, Zhanel GG, Alliance CAR. Invasive Streptococcus pneumoniae in Canada, 2011–2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. 2016;34:2527–30.CrossRefPubMed Golden AR, Adam HJ, Zhanel GG, Alliance CAR. Invasive Streptococcus pneumoniae in Canada, 2011–2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. Vaccine. 2016;34:2527–30.CrossRefPubMed
Metadata
Title
Epidemiology of invasive pneumococcal disease in indigenous and non-indigenous adults in northwestern Ontario, Canada, 2006–2015
Authors
Daniel Dalcin
Lee Sieswerda
Sacha Dubois
Marina Ulanova
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3531-9

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.